Login
Navigate Fool.com
Will ALKS beat
the market?

Alkermes, Inc.

NASDAQ: ALKS

Community Rating: 3 Stars: Appealing

45.03 2.20 (5.14%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $43.09
Previous Close $42.83
Daily Range $42.59 - $45.18
52-Week Range $24.42 - $54.25
Market Cap $6.5B
P/E Ratio 611.86
Dividend (Yield) $0.00 (0.0%)
Volume 1,654,995
Average Daily Volume 1,676,502
Current FY EPS $0.17

How do you think ALKS
will perform against the market?

Top ALKS Bull/Bear Pitches

 

lovinoptions (< 20)
Submitted July 24, 2009

Very high profit margin <br /><br /> <br /><br />Very low P/E <br /><br /> <br /><br />Very high forward P/E <br /><br /> <br /><br />Earnings expected to grow at a rate of 42% over the next 5 years. … More

0 Replies Reply Report this Post
 

PickThatBooger (< 20)
Submitted November 15, 2010

Almost got the top on this one.

0 Replies Reply Report this Post

News & Commentary

The Biggest Biotech Wins of the Week

Find out which biotech and pharmaceutical companies posted the best clinical results for the week ending April 11.

This Week in Biotech: The Questcor Buyout and MannKind's Giant Leap to Nowhere

A surprise buyout, MannKind's sanguine PDUFA update regarding Afrezza, and three positive clinical studies, mark this week's top biotech stories.

Healthcare Stocks Losing Ground Ahead of Closing Bell; Alkermes Up 3% on Positive Results for Schizo

Healthcare Stocks Losing Ground Ahead of Closing Bell; Alkermes Up 3% on Positive Results for Schizophrenia Drug

Sector Update: Healthcare

Why Alkermes PLC Shares Temporarily Spiked Higher

Alkermes presents top-line results from a late-stage schizophrenia study before the opening bell. Can its shares head even higher?

Alkermes Scores Phase 3 Win for Long-Lasting Schizophrenia Drug

Alkermes scores phase 3 win for long-lasting schizophrenia drug.

Why Tesla Motors, Acceleron Pharma, and Ballard Power Systems Jumped Today

The Dow finished just below its all-time highs, but the market's overall gains were small compared to these three stocks. Find out more about what made them soar.

New Stock Coverage: 57 Cents Could Cost General Motors Billions

Wall Street ratings agencies set the tone for today's stock market.

New Stock Coverage: General Motors, Ford, and Alkermes

Wall Street ratings agencies set the tone for today's stock market.

Top Analyst Upgrades and Downgrades: Apollo Education, Ford, GM, Alkermes, Cognizant and More

See More ALKS News...

Sector

Healthcare

Industry

Drugs

Alkermes, Inc. (ALKS) Description

A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Website: http://www.alkermes.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks